Successful HeartMate 3 implantation in isolated right heart failure—first in man experience of right heart configuration

Ricklefs, Marcel; Hanke, Jasmin S.; Dogan, Guenes; Chatterjee, Arijit; Feldmann, C.; Deniz, E.; Korte, Wilhelm; Kirchhoff, F.; Haverich, Axel; Schmitto, Jan D.

doi:10.21037/jtd.2018.05.35

Cited by 13 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After 8 days, a HeartMate 3 (Abbott, Chicago, Ill) LVAD was implanted as a bridge to recovery. 1 , 2 Forty-two days later, the right ventricle showed sufficient recovery, and the temporary mechanical support was weaned off and a dual-chamber permanent pacemaker was implanted for complete heart block. However, 5 months later, the right ventricle failed again, tricuspid regurgitation became severe (mean right atrial pressure of 20 mm Hg), and a durable RVAD was needed.…”

Section: Clinical Summarymentioning

confidence: 99%

Dynamic superior vena cava occlusion with an atrial implanted pediatric right ventricular assist device

et al. 2021

View full text Add to dashboard Cite

Video clip is available online.A HeartMate 3 right ventricular assist device (RVAD) was implanted 5 months after a left ventricular assist device (LVAD) in a pediatric patient, due to late onset of right heart failure and deterioration of right ventricular function that did not respond to maximal medical therapy. Herein, we describe the early manifestation of a dynamic superior vena cava occlusion syndrome due to RVAD suction effect that was successfully managed.

show abstract

Section: Clinical Summarymentioning

confidence: 99%

Dynamic superior vena cava occlusion with an atrial implanted pediatric right ventricular assist device

et al. 2021

View full text Add to dashboard Cite

show abstract

“…7 Some groups have reported biventricular support by HVAD or HM3 in the clinical setting, but there is a lack of in vitro hemodynamic evaluation of the HM3 used as an RVAD for RHF. [8][9][10][11][12][13] Most notably, in their review of continuous-flow BVAD outcomes in 2021, Farag et al identified eight studies that used an HVAD for RVAD and three studies that used the HM3 for RVAD. 14 Although the HVAD is not available in the market, comparison with successful CF technologies such as the HVAD and HM3 represent value to study clinical characteristics of CF pumps used as BVAD configurations.…”

Section: Introductionmentioning

confidence: 99%

“…The clinical options for RVAD support are currently limited to two implantable LVADs or temporary device support, and implantation modalities may vary depending on the individual surgeon’s decision and device availability 7 . Some groups have reported biventricular support by HVAD or HM3 in the clinical setting, but there is a lack of in vitro hemodynamic evaluation of the HM3 used as an RVAD for RHF 8–13 . Most notably, in their review of continuous‐flow BVAD outcomes in 2021, Farag et al identified eight studies that used an HVAD for RVAD and three studies that used the HM3 for RVAD 14 .…”

Section: Introductionmentioning

confidence: 99%

Evaluation of centrifugal blood pump performances for biventricular support in the virtual simulation model

Kuroda

Miyamoto

Horvath³

et al. 2022

Artificial Organs

View full text Add to dashboard Cite

Background Despite the advances in the left ventricular assist device (LVAD), there are still situations that require a biventricular assist device (BVAD) system. The purpose of this study was to explore and compare the system performance interactions with the HeartMate3 (HM3) and HeartWare (HVAD) in a BVAD configuration using the virtual mock loop (VML) simulation tool. Methods The VML simulation tool is an in silico implementation of a lumped parameter model of the cardiovascular system with mechanical circulatory support. Patients with ejection fractions of 60%, 20%, and 15% were simulated in VML, and the HVAD and HM3 in a BVAD with ventricular cannulation were applied to simulated conditions. Pump speeds that restored baseline normal hemodynamics were determined. To determine the optimal speeds for BVAD, the left and right arterial pressures (LAP, RAP) were plotted. Results In the HVAD, LAP and RAP are balanced at 11 mm Hg with LVAD 3500 rpm, right ventricular assist device (RVAD) 2200 rpm; at 13 mm Hg with LVAD 3000 rpm, RVAD 1700 rpm; and at 14 mm Hg with LVAD 2500 rpm, RVAD 1300 rpm. For the HM3, at 8 mm Hg with LVAD 7000 rpm, RVAD 5000 rpm; at 9 mm Hg with LVAD 6000 rpm, RVAD 4300 rpm; and at 9.5 mm Hg with LVAD 5000 rpm, RVAD 3500 rpm. Conclusion The RVAD/LVAD speed ratios required for atrial balance were approximately 0.6 for the HVAD and 0.7 for the HM3. However, the HVAD required RVAD speeds below its range of operation.

show abstract

“…1 The HVAD (HeartWare, Framingham, MA) and HeartMate 3 (Abbott, North Chicago, IL-HM3) have been reportedly used for biventricular support but isolated right ventricular assist device (RVAD) implantation is still rare. [2][3][4]…”

mentioning

confidence: 99%

Do it “RIGHT”: HeartMate 3 as Destination Therapy Right Ventricular Assist Device in a Patient With Arrhythmogenic Right Ventricular Cardiomyopathy

et al. 2022

View full text Add to dashboard Cite

Isolated right ventricular failure presents a rare pathology and heart transplantation remains the treatment of choice. Because of the shortage of donor organs, alternative treatment options are required. However, current continuous-flow ventricular assist devices are designed and approved only for left ventricular support and right ventricular implantation usually presents a procedure of last resort. Herein, we present a successful implantation of the HeartMate 3 for isolated right ventricular support as destination therapy in a patient suffering from late-onset arrhythmogenic right ventricular cardiomyopathy.

show abstract

Successful HeartMate 3 implantation in isolated right heart failure—first in man experience of right heart configuration

Cited by 13 publications

References 11 publications

Dynamic superior vena cava occlusion with an atrial implanted pediatric right ventricular assist device

Dynamic superior vena cava occlusion with an atrial implanted pediatric right ventricular assist device

Evaluation of centrifugal blood pump performances for biventricular support in the virtual simulation model

Do it “RIGHT”: HeartMate 3 as Destination Therapy Right Ventricular Assist Device in a Patient With Arrhythmogenic Right Ventricular Cardiomyopathy

Contact Info

Product

Resources

About